Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EPS (Basic) (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported EPS (Basic) over the past 12 years, most recently at -$73.84 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$73.84 for Q4 2025, down 36.14% from a year ago — trailing twelve months through Dec 2025 was -$133.12 (up 34.84% YoY), and the annual figure for FY2025 was -$221.65, down 8.22%.
  • EPS (Basic) for Q4 2025 was -$73.84 at Viridian Therapeutics, Inc.\DE, down from -$0.34 in the prior quarter.
  • Over the last five years, EPS (Basic) for VRDN hit a ceiling of -$0.34 in Q3 2025 and a floor of -$256.73 in Q4 2023.
  • Median EPS (Basic) over the past 5 years was -$1.91 (2021), compared with a mean of -$39.31.
  • Biggest five-year swings in EPS (Basic): tumbled 24991.55% in 2022 and later skyrocketed 99.42% in 2025.
  • Viridian Therapeutics, Inc.\DE's EPS (Basic) stood at -$0.71 in 2021, then tumbled by 24991.55% to -$178.15 in 2022, then plummeted by 44.11% to -$256.73 in 2023, then skyrocketed by 78.87% to -$54.24 in 2024, then plummeted by 36.14% to -$73.84 in 2025.
  • The last three reported values for EPS (Basic) were -$73.84 (Q4 2025), -$0.34 (Q3 2025), and -$1.0 (Q2 2025) per Business Quant data.